One study further elucidated that PPARγ agonists improve cognitive function by inhibiting inflammation and reducing apoptosis, an effect mediated by activation of the PPARγ/NF-κB signaling pathway, suggesting that PPARγ agonists may serve as potential therapeutic agents for the treatment of AD (218). Here, NFKB1 is linked to Alzheimer disease.